SCHEMBL3666149

SCHEMBL3666149

CC(C)NC(=O)N(C)C1CCN(c2cc[c]cn2)C(C(N)=O)C1

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.32
USP30 Q70CQ3 3/20 0.32
TSHR P16473 1/20 0.32
JAK3 P52333 2/20 0.32
JAK1 P23458 1/20 0.31
HTR2A P28223 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3662349 0.87 AAK1 (0.35)
SCHEMBL3811668 0.85 CCR5 (0.40) JAK3JAK1
SCHEMBL3666953 0.83 KDM4E (0.34) USP30
SCHEMBL3666600 0.83 JAK2 (0.34) JAK3JAK1
SCHEMBL3666818 0.83 JAK2 (0.35) JAK3JAK1
SCHEMBL3668762 0.82 USP30 (0.34) USP30JAK3
SCHEMBL3663776 0.82 JAK3 (0.33) JAK3JAK1
SCHEMBL3668423 0.82 JAK2 (0.43) JAK3JAK1
SCHEMBL3666932 0.81 POLB (0.34) PIK3CDJAK3JAK1
SCHEMBL3811881 0.81 CCR5 (0.40) JAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PIK3CD 490/4885USP30 2677/4885TSHR 2277/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PIK3CD 490/4885USP30 2677/4885TSHR 2277/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PIK3CD 490/4885USP30 2677/4885TSHR 2277/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PIK3CD 490/4885USP30 2677/4885TSHR 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.